3,4-Diarylmaleimides-a novel class of kinase inhibitors-effectively induce apoptosis in FLT3-ITD-dependent cells

Annals of Hematology

Volumn 91, Issue 3, 2012, Pages 331-344

  Heidel, Florian H ^a   MacK, Thomas S ^a   Razumovskaya, Elena ^b   Blum, Marie Christine ^a   Lipka, Daniel B ^a   Ballaschk, Anne ^a   Kramb, Jan Peter ^c   Plutizki, Stanislav ^c   Rönnstrand, Lars ^b   Dannhardt, Gerd ^c   Fischer, Thomas ^a  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

^b LUND UNIVERSITY   (Sweden)

^c JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

AML; FLT3; Tyrosine kinase inhibitor; Tyrosine phosphorylation

Indexed keywords

3,4 DIARYLMALEIMIDE DERIVATIVE; ADENOSINE TRIPHOSPHATE; CD135 ANTIGEN; CYTARABINE; DAUNORUBICIN; DHF 125; DHF 150; MALEIMIDE DERIVATIVE; MIDOSTAURIN; PROTEIN TYROSINE KINASE INHIBITOR; TYROSINE; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ANIMAL CELL; APOPTOSIS; ARTICLE; AUTOPHOSPHORYLATION; BLAST CELL; CANCER CELL; CANCER CELL CULTURE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOPLASM; DRUG EFFICACY; DRUG POTENTIATION; DRUG STRUCTURE; DRUG TARGETING; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FEMALE; GENE DUPLICATION; HUMAN; HUMAN CELL; IC 50; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; APOPTOSIS; CLINICAL TRIALS AS TOPIC; FEMALE; FMS-LIKE TYROSINE KINASE 3; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MALEIMIDES; MICE; MIDDLE AGED; PROTEIN KINASE INHIBITORS; STEM CELLS; TUMOR CELLS, CULTURED;

EID: 84857359937     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-011-1311-3     Document Type: Article

References (42)

1. JE Godwin KJ Kopecky DR Head CL Willman CP Leith HE Hynes SP Balcerzak FR Appelbaum 1998 A double-blind placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group Study (9031) Blood 91 10 3607 3615 9572995 1:CAS:528:DyaK1cXjtFersrY%3D (Pubitemid 28225726)
2. AH Goldstone AK Burnett K Wheatley AG Smith RM Hutchinson RE Clark 2001 Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial Blood 98 5 1302 1311 10.1182/blood.V98.5.1302 11520775 10.1182/blood.V98.5.1302 1:CAS:528:DC%2BD3MXmvFGjtr8%3D
3. B Lowenberg S Suciu E Archimbaud H Haak P Stryckmans R de Cataldo AW Dekker ZN Berneman A Thyss J van der Lelie P Sonneveld G Visani G Fillet M Hayat A Hagemeijer G Solbu R Zittoun 1998 Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy-the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon Group J Clin Oncol 16 3 872 881 9508168 1:CAS:528: DyaK1cXitVKis7g%3D (Pubitemid 28115455)
4. RJ Mayer RB Davis CA Schiffer DT Berg BL Powell P Schulman GA Omura JO Moore OR McIntyre E Frei The Cancer and Leukemia Group B 1994 Intensive postremission chemotherapy in adults with acute myeloid leukemia N Engl J Med 331 14 896 903 10.1056/nejm199410063311402 8078551 10.1056/NEJM199410063311402 1:STN:280:DyaK2czlvFGluw%3D%3D (Pubitemid 24299870)
5. RM Stone DT Berg SL George RK Dodge PA Paciucci P Schulman EJ Lee JO Moore BL Powell CA Schiffer The Cancer and Leukemia Group B 1995 Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia N Engl J Med 332 25 1671 1677 10.1056/nejm199506223322503 7760868 10.1056/NEJM199506223322503 1:STN:280:DyaK2M3otV2ktA%3D%3D
6. K Mrozek NA Heerema CD Bloomfield 2004 Cytogenetics in acute leukemia Blood Rev 18 2 115 136 15010150 10.1016/S0268-960X(03)00040-7 (Pubitemid 38380667)
7. C Langer MD Radmacher AS Ruppert SP Whitman P Paschka K Mrozek CD Baldus T Vukosavljevic CG Liu ME Ross BL Powell A de la Chapelle JE Kolitz RA Larson G Marcucci CD Bloomfield 2008 High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: a Cancer and Leukemia Group B (CALGB) study Blood 111 11 5371 5379 18378853 10.1182/blood-2007-11-124958 1:CAS:528:DC%2BD1cXntFWns7g%3D
8. G Marcucci K Maharry SP Whitman T Vukosavljevic P Paschka C Langer K Mrozek CD Baldus AJ Carroll BL Powell JE Kolitz RA Larson CD Bloomfield 2007 High expression levels of the ETS-related gene, ERG, predict adverse outcome and improve molecular risk-based classification of cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B Study J Clin Oncol 25 22 3337 3343 17577018 10.1200/JCO.2007.10.8720 1:CAS:528:DC%2BD2sXhtVWqs7jJ (Pubitemid 47325620)
9. K Mrozek H Dohner CD Bloomfield 2007 Influence of new molecular prognostic markers in patients with karyotypically normal acute myeloid leukemia: recent advances Curr Opin Hematol 14 2 106 114 17255787 10.1097/MOH.0b013e32801684c7 1:CAS:528:DC%2BD2sXis1yisbY%3D (Pubitemid 46175094)
10. M Heuser G Beutel J Krauter K Dohner N von Neuhoff B Schlegelberger A Ganser 2006 High meningioma 1 (MN1) expression as a predictor for poor outcome in acute myeloid leukemia with normal cytogenetics Blood 108 12 3898 3905 16912223 10.1182/blood-2006-04-014845 1:CAS:528:DC%2BD28Xht1Kgs7rM (Pubitemid 44864574)
11. K Dohner RF Schlenk M Habdank C Scholl FG Rucker A Corbacioglu L Bullinger S Frohling H Dohner 2005 Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations Blood 106 12 3740 3746 16051734 10.1182/blood-2005-05-2164 (Pubitemid 41739007)
12. S Frohling RF Schlenk I Stolze J Bihlmayr A Benner S Kreitmeier K Tobis H Dohner K Dohner 2004 CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations J Clin Oncol 22 4 624 633 14726504 10.1200/JCO.2004.06.060 (Pubitemid 41095065)
13. P Paschka G Marcucci AS Ruppert SP Whitman K Mrozek K Maharry C Langer CD Baldus W Zhao BL Powell MR Baer AJ Carroll MA Caligiuri JE Kolitz RA Larson CD Bloomfield 2008 Wilms tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B Study J Clin Oncol 26 28 4595 4602 18559874 10.1200/JCO.2007.15.2058 1:CAS:528:DC%2BD1cXht1KqtLfJ
14. S Frohling RF Schlenk J Breitruck A Benner S Kreitmeier K Tobis H Dohner K Dohner 2002 Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm Blood 100 13 4372 4380 12393388 10.1182/blood-2002-05-1440 1:CAS:528:DC%2BD38XpsFCqsL4%3D (Pubitemid 35434129)
15. C Thiede C Steudel B Mohr M Schaich U Schakel U Platzbecker M Wermke M Bornhauser M Ritter A Neubauer G Ehninger T Illmer 2002 Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis Blood 99 12 4326 4335 12036858 10.1182/blood.V99.12.4326 1:CAS:528:DC%2BD38XksFGlu7o%3D (Pubitemid 34627197)
16. F Breitenbuecher S Schnittger R Grundler B Markova B Carius A Brecht J Duyster T Haferlach C Huber T Fischer 2009 Identification of a novel type of ITD mutations located in nonjuxtamembrane domains of the FLT3 tyrosine kinase receptor Blood 113 17 4074 4077 18483393 10.1182/blood-2007-11-125476 1:CAS:528:DC%2BD1MXlsVWrtrw%3D
17. M Nakao S Yokota T Iwai H Kaneko S Horiike K Kashima Y Sonoda T Fujimoto S Misawa 1996 Internal tandem duplication of the flt3 gene found in acute myeloid leukemia Leukemia 10 12 1911 1918 8946930 1:STN:280:DyaK2s7gt1Kqsg%3D%3D (Pubitemid 27019637)
18. S Yokota H Kiyoi M Nakao T Iwai S Misawa T Okuda Y Sonoda T Abe K Kahsima Y Matsuo T Naoe 1997 Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies. A study on a large series of patients and cell lines Leukemia 11 10 1605 1609 9324277 10.1038/sj.leu.2400812 1:CAS:528:DyaK2sXnsV2iu7k%3D (Pubitemid 27458595)
19. RE Gale C Green C Allen AJ Mead AK Burnett RK Hills DC Linch 2008 The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia Blood 111 5 2776 2784 17957027 10.1182/blood-2007-08- 109090 1:CAS:528:DC%2BD1cXivFaktbY%3D
20. S Kayser RF Schlenk M Correa Londono F Breitenbuecher K Wittke J Du S Groner D Spath J Krauter A Ganser H Dohner T Fischer K Dohner 2009 Insertion of FLT3 internal tandem duplication in the tyrosine kinase domain-1 is associated with resistance to chemotherapy and inferior outcome Blood 114 12 2386 2392 19602710 10.1182/blood-2009-03-209999 1:CAS:528:DC%2BD1MXht1WktrzN
21. J Griffith J Black C Faerman L Swenson M Wynn F Lu J Lippke K Saxena 2004 The structural basis for autoinhibition of FLT3 by the juxtamembrane domain Mol Cell 13 2 169 178 14759363 10.1016/S1097-2765(03)00505-7 1:CAS:528: DC%2BD2cXhsFOiu7g%3D (Pubitemid 38183264)
22. LM Kelly Q Liu JL Kutok IR Williams CL Boulton DG Gilliland 2002 FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model Blood 99 1 310 318 11756186 10.1182/blood.V99.1.310 1:CAS:528: DC%2BD38XivF2gtQ%3D%3D (Pubitemid 34532998)
23. J Cools N Mentens P Furet D Fabbro JJ Clark JD Griffin P Marynen DG Gilliland 2004 Prediction of resistance to small molecule FLT3 inhibitors: implications for molecularly targeted therapy of acute leukemia Cancer Res 64 18 6385 6389 15374944 10.1158/0008-5472.CAN-04-2148 1:CAS:528:DC%2BD2cXnsFOlt7c%3D (Pubitemid 39297890)
24. F Heidel FK Solem F Breitenbuecher DB Lipka S Kasper MH Thiede C Brandts H Serve J Roesel F Giles E Feldman G Ehninger GJ Schiller S Nimer RM Stone Y Wang T Kindler PS Cohen C Huber T Fischer 2006 Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain Blood 107 1 293 300 16150941 10.1182/blood-2005-06-2469 1:CAS:528:DC%2BD28XhsVGlsQ%3D%3D (Pubitemid 43053554)
25. C Graf F Heidel S Tenzer MP Radsak FK Solem CM Britten C Huber T Fischer T Wolfel 2007 A neoepitope generated by an FLT3 internal tandem duplication (FLT3-ITD) is recognized by leukemia-reactive autologous CD8+ T cells Blood 109 7 2985 2988 17119119 1:CAS:528:DC%2BD2sXjvVynsbs%3D (Pubitemid 46482098)
26. Dannhardt G, Fischer T, Heidel F, Peifer C, Plutizki S, Kramb JP (2007) Use of 3-(4-indolyl)- or 3-(azaindolyl)-4-arylmaleimide derivatives in leukemia management. Patent no. WO 2009/071620 A1.
27. C Peifer A Krasowski N Hammerle O Kohlbacher G Dannhardt F Totzke C Schachtele S Laufer 2006 Profile and molecular modeling of 3-(indole-3-yl)-4-(3, 4,5-trimethoxyphenyl)-1 H-pyrrole-2,5-dione (1) as a highly selective VEGF-R2/3 inhibitor J Med Chem 49 25 7549 7553 17149885 10.1021/jm0609871 1:CAS:528:DC%2BD28XhtF2gt7vJ (Pubitemid 44913415)
28. C Peifer T Stoiber E Unger F Totzke C Schachtele D Marme R Brenk G Klebe D Schollmeyer G Dannhardt 2006 Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors J Med Chem 49 4 1271 1281 16480264 10.1021/jm0580297 1:CAS:528:DC%2BD28XpsVKhsA%3D%3D (Pubitemid 43273496)
29. E Razumovskaya K Masson R Khan S Bengtsson L Ronnstrand 2009 Oncogenic Flt3 receptors display different specificity and kinetics of autophosphorylation Exp Hematol 37 979 989 19477218 10.1016/j.exphem.2009.05.008 1:CAS:528:DC%2BD1MXos12ku7s%3D
30. TC Chou 2006 Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies Pharmacol Rev 58 3 621 681 16968952 10.1124/pr.58.3.10 1:CAS:528:DC%2BD28XhtVOhtLfL (Pubitemid 44403686)
31. DB Lipka LS Hoffmann F Heidel B Markova MC Blum F Breitenbuecher S Kasper T Kindler RL Levine C Huber T Fischer 2008 LS104, a non-ATP-competitive small-molecule inhibitor of JAK2, is potently inducing apoptosis in JAK2V617F-positive cells Mol Cancer Ther 7 5 1176 1184 18483305 10.1158/1535-7163.MCT-07-2215 1:CAS:528:DC%2BD1cXlvFamsr8%3D
32. E Weisberg C Boulton LM Kelly P Manley D Fabbro T Meyer DG Gilliland JD Griffin 2002 Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412 Cancer Cell 1 5 433 443 12124173 10.1016/S1535-6108(02)00069-7 1:CAS:528:DC%2BD38XltVKjsb4%3D (Pubitemid 41039124)
33. F Heidel DB Lipka FK Mirea S Mahboobi R Grundler RK Kancha J Duyster M Naumann C Huber FD Bohmer T Fischer 2009 Bis(1H-indol-2-yl)methanones are effective inhibitors of FLT3-ITD tyrosine kinase and partially overcome resistance to PKC412A in vitro Br J Haematol 144 6 865 874 19183186 10.1111/j.1365-2141.2008.07567.x 1:CAS:528:DC%2BD1MXkt12ntLc%3D
34. S Kasper F Breitenbuecher Y Hoehn F Heidel DB Lipka B Markova C Huber T Kindler T Fischer 2008 The kinase inhibitor LS104 induces apoptosis, enhances cytotoxic effects of chemotherapeutic drugs and is targeting the receptor tyrosine kinase FLT3 in acute myeloid leukemia Leuk Res 32 11 1698 1708 18556063 10.1016/j.leukres.2008.05.003 1:CAS:528:DC%2BD1cXoslWmurs%3D
35. T Fischer RM Stone DJ Deangelo I Galinsky E Estey C Lanza E Fox G Ehninger EJ Feldman GJ Schiller VM Klimek SD Nimer DG Gilliland C Dutreix A Huntsman-Labed J Virkus FJ Giles 2010 Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3 J Clin Oncol 28 28 4339 4345 10.1200/JCO.2010.28.9678 20733134 10.1200/JCO.2010.28.9678 1:CAS:528:DC%2BC3cXhtl2ks7vL
36. RM Stone DJ DeAngelo V Klimek I Galinsky E Estey SD Nimer W Grandin D Lebwohl Y Wang P Cohen EA Fox D Neuberg J Clark DG Gilliland JD Griffin 2005 Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412 Blood 105 1 54 60 10.1182/blood-2004-03-0891 15345597 10.1182/blood-2004-03-0891 1:CAS:528:DC%2BD2MXis1GksA%3D%3D (Pubitemid 40053063)
37. M Levis J Allebach KF Tse R Zheng BR Baldwin BD Smith S Jones-Bolin B Ruggeri C Dionne D Small 2002 A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo Blood 99 11 3885 3891 12010785 10.1182/blood.V99.11.3885 1:CAS:528:DC%2BD38XktFyrsr0%3D (Pubitemid 35332023)
38. PP Zarrinkar RN Gunawardane MD Cramer MF Gardner D Brigham B Belli MW Karaman KW Pratz G Pallares Q Chao KG Sprankle HK Patel M Levis RC Armstrong J James SS Bhagwat 2009 AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML) Blood 114 14 2984 2992 19654408 10.1182/blood-2009-05-222034 1:CAS:528:DC%2BD1MXht12qurzN
39. NP Shah C Kasap C Weier M Balbas JM Nicoll E Bleickardt C Nicaise CL Sawyers 2008 Transient potent BCR-ABL inhibition is sufficient to commit chronic myeloid leukemia cells irreversibly to apoptosis Cancer Cell 14 6 485 493 19061839 10.1016/j.ccr.2008.11.001 1:CAS:528:DC%2BD1cXhsFahsrfF
40. S Huber M Oelsner T Decker CM Zum Buschenfelde M Wagner G Lutzny T Kuhnt B Schmidt RA Oostendorp C Peschel I Ringshausen 2011 Sorafenib induces cell death in chronic lymphocytic leukemia by translational downregulation of Mcl-1 Leukemia 25 5 838 847 10.1038/leu.2011.2 21293487 10.1038/leu.2011.2 1:CAS:528:DC%2BC3MXlvFCksr0%3D
41. JL Rocnik R Okabe JC Yu BH Lee N Giese DP Schenkein DG Gilliland 2006 Roles of tyrosine 589 and 591 in STAT5 activation and transformation mediated by FLT3-ITD Blood 108 4 1339 1345 16627759 10.1182/blood-2005-11-011429 1:CAS:528:DC%2BD28Xot1ymurk%3D (Pubitemid 44232034)
42. S Vempati C Reindl U Wolf R Kern K Petropoulos VM Naidu C Buske W Hiddemann TM Kohl K Spiekermann 2008 Transformation by oncogenic mutants and ligand-dependent activation of FLT3 wild-type requires the tyrosine residues 589 and 591 Clin Cancer Res 14 14 4437 4445 18628457 10.1158/1078-0432.CCR-07-1873 1:CAS:528:DC%2BD1cXosFGit7s%3D